“…In recent times, it has been reported as a novel inflammatory indicator for prognosis in various cancers, such as colorectal cancer, lung cancer, esophageal cancer, and breast cancer. 23 This study established RIs for the albumin to globulin ratio, which had not been provided by the manufacturer of reagents in France 15 or in the study conducted by Bossuyt et al in Belgium, 13 or with other published RIs in Belgium, 13,14 the USA, 17 Switzerland, 18 Italy, 20,21 Japan, 19 and France. 22 Except for beta-2 globulin, the RIs established in the current study had a higher upper percentile in all globulin fractions (alpha-1 globulin, alpha-2 globulin, beta-1 globulin, beta-2 globulin, and gamma globulin) compared to the values provided by the reagent manufacturer in France.…”